US launches Section 301 probe into Germany over drug pricing
The US has launched an investigation into Germany's underpayment for innovative pharmaceutical products, citing concerns over unfair trade practices and reduced spending on these products.
- Country:
- United States
The United States has initiated an investigation under Section 301 of the Trade Act of 1974 against Germany, U.S. Trade Representative Jamieson Greer said on Thursday.
The investigation will seek to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory, the USTR said. "I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals," Greer said. The German Embassy in Washington did not immediately respond to a request for comment. The trade representative will open a docket for submission of written comments on June 25 and its Section 301 Committee will hold a public hearing on the probe in September.
ALSO READ
-
US launches trade investigation into Germany over drug pricing
-
US launches Section 301 probe into Germany over drug pricing
-
Carney says Canada, US held detailed, technical trade talks at G7
-
Soccer-Germany keeper Neuer will retire from national team again after World Cup
-
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett
Google News